Menlo Therapeutics

OverviewSuggest Edit

Menlo Therapeutics is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause.

TypePublic
Founded2011
HQRedwood City, CA, US
Websitevynetherapeutics.com

Latest Updates

Employees (est.) (Jan 2018)26
Revenue (Y, 2017)$2 M
Share Price (Jan 2021)$2.2(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Menlo Therapeutics

David Domzalski

David Domzalski

President and Chief Executive Officer, Director
Matt Wiley

Matt Wiley

Chief Commercial Officer
Iain Stuart

Iain Stuart

Chief Scientific Officer
Mutya Harsch

Mutya Harsch

General Counsel, Chief Legal Officer and Secretary
Ray Steitz

Ray Steitz

Senior Vice President, Global Human Resources
Russell Elliott

Russell Elliott

Senior Vice President, Pharmaceutical Development
Show more

Menlo Therapeutics Office Locations

Menlo Therapeutics has offices in Redwood City, Bridgewater Township and Ness Ziona
Redwood City, CA, US (HQ)
200 Cardinal Way
Bridgewater Township, NJ, US
520 US-22 #204
Ness Ziona, IL
3rd floor, Golda Me'ir St 7
Show all (3)

Menlo Therapeutics Financials and Metrics

Menlo Therapeutics Revenue

Menlo Therapeutics's revenue was reported to be $2 m in Y, 2017
USD

Revenue (Y, 2017)

2.0m

Market capitalization (28-Jan-2021)

82.5m

Closing stock price (28-Jan-2021)

2.2
Menlo Therapeutics's current market capitalization is $82.5 m.
USDY, 2017

Revenue

2.0m
Show all financial metrics

Menlo Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Menlo Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Menlo Therapeutics Online and Social Media Presence

Embed Graph

Menlo Therapeutics News and Updates

Menlo Therapeutics Announces Pricing of Offering of Common Stock

BRIDGEWATER, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the pricing of an underwritten public off…

Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix”) following the satisfaction of all closing conditions required by the merge…

Menlo Therapeutics shares slide 25% premarket after trial of treatment for severe itching fails to meet goals

Menlo Therapeutics Inc. shares slid 25% in premarket trade Wednesday, after the biopharmaceutical company said a mid-stage trial of a treatment for chronic pruritus, a form of skin itching, of unknown origin failed to meet its main goal. The trial involved 233 patients and sought to show a statisti…

Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

Menlo to Host Conference Call Today at 8:30 AM Eastern Time; Foamix’s CEO David Domzalski will be Available for Q&A Menlo to Host Conference Call Today at 8:30 AM Eastern Time; Foamix’s CEO David Domzalski will be Available for Q&A

Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of…

Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Psoriasis in the Journal of the American Academy of Dermatology

REDWOOD CITY, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of serlopitant for t…
Show more

Menlo Therapeutics Blogs

KOL Event: Novel InhiBET BET Inhibitor Platform

KOL Event – Novel InhiBET BET Inhibitor Platform

VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBETTM BET inhibitor platform on May 17th   BRIDGEWATER, N.J., May 12, 2022 (GLO…

VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event

BRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022. Abo…

VYNE Investor Relations Presentation

Download: November 10, 2021

VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

BRIDGEWATER, N.J., May 06, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. “Our sales organization continues to drive utilization of AMZEEQ and ZILXI,…

VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Confe…
Show more

Menlo Therapeutics Frequently Asked Questions

  • When was Menlo Therapeutics founded?

    Menlo Therapeutics was founded in 2011.

  • Who are Menlo Therapeutics key executives?

    Menlo Therapeutics's key executives are David Domzalski, Matt Wiley and Iain Stuart.

  • How many employees does Menlo Therapeutics have?

    Menlo Therapeutics has 26 employees.

  • What is Menlo Therapeutics revenue?

    Latest Menlo Therapeutics annual revenue is $2 m.

  • What is Menlo Therapeutics revenue per employee?

    Latest Menlo Therapeutics revenue per employee is $76.9 k.

  • Who are Menlo Therapeutics competitors?

    Competitors of Menlo Therapeutics include BlueRock Therapeutics, Celularity and Lattice Biologics.

  • Where is Menlo Therapeutics headquarters?

    Menlo Therapeutics headquarters is located at 200 Cardinal Way, Redwood City.

  • Where are Menlo Therapeutics offices?

    Menlo Therapeutics has offices in Redwood City, Bridgewater Township and Ness Ziona.

  • How many offices does Menlo Therapeutics have?

    Menlo Therapeutics has 3 offices.